ADMA Biologics/ADMA

$5.52

2.61%
-
1D1W1MYTD1YMAX

About ADMA Biologics

ADMA Biologics, Inc. is a commercial biopharmaceutical company. It develops, manufactures, and markets specialty plasma-derived biologics for the treatment and prevention of infectious diseases. It is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its patients include immune-compromised individuals who suffer from an underlying immune deficiency disorder and immune-suppressed for medical reasons. Its product includes BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV an IVIG product indicated for the treatment of PI, and Nabi-HB which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg). Its ADMA BioCenters subsidiary operates over 10 source plasma collection facilities in the United States. Its Plasma Collection Centers segment provides a portion of its blood plasma for the manufacture of its products.

Ticker

ADMA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Adam Grossman

Employees

624

Headquarters

Ramsey, United States

ADMA Biologics Metrics

BasicAdvanced
$1.26B
Market cap
-
P/E ratio
-$0.13
EPS
0.44
Beta
-
Dividend rate

What the Analysts think about ADMA Biologics

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
44.93% upside
High $10.00
Low $6.00
$5.52
Current price
$8.00
Average price target

ADMA Biologics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-23.81% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$73.9M
9.97%
Net income
$-17.6M
-804%
Profit margin
-23.81%
-740.05%

ADMA Biologics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 420%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.03
-$0.03
$0.01
-$0.08
-
Expected
-$0.04
-$0.03
-$0.01
$0.03
$0.05
Surprise
-29.41%
20%
-233.33%
-420%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell ADMA Biologics stock

Buy or sell ADMA Biologics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing